ClinicalTrials.gg
RecruitingNCT07564596Updated Oct 20, 2026

A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE)

A Phase 1/2 interventional study of Budoprutug in Systemic Lupus Erthematosus, sponsored by Climb Bio, Inc.. Recruiting at 10 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Climb Bio, Inc. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Oct 20, 20268 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Budoprutug is a humanized, immunoglobulin (Ig) G1 monoclonal antibody that selectively binds to CD19 and is projected to deplete targeted cells through antibody-dependent cellular cytotoxicity. This Phase 1b/2a, open-label study will evaluate budoprutug in ascending dose cohorts of patients aged 18 years and above with active, seropositive SLE and inadequate response to standard therapy. The study will also assess the pharmacokinetics, pharmacodynamics and early indications of efficacy of budoprutug in SLE, where pharmacodynamics will be evaluated as the change in the number of B cells and immunoglobulins (antibodies) in the blood over time. Budoprutug will be administered as two (2) IV infusions 14 days apart in ascending dose cohorts.

02

Conditions studied

  • Systemic Lupus Erthematosus

Keywords

  • Lupus
  • SLE
  • Biologics
  • Open-label
  • Monoclonal
  • anti-CD19
03

In context

Lead sponsor

Climb Bio, Inc. is the lead sponsor of 6 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 to 65 years at the time of consent.
  2. Diagnosis of SLE according to the 2019 European League Against. Rheumatism and the American College of Rheumatology (ACR) classification criteria.
  3. Active, seropositive disease, with SLEDAI 2K >=6 at screening
  4. Inadequate response to at least one therapeutic intervention

Exclusion criteria

Exclusion Criteria:

  1. Active neuropsychiatric SLE.
  2. Active lupus nephritis type III or IV that is expected to require induction therapy during the study or recently treated with induction therapy within 12 weeks.
  3. Prior diagnosis of, or fulfills diagnostic criteria for, other or inflammatory disease that may confound clinical assessments or increase subject risk in the study
  4. Active systemic infection or history of chronic, recurrent, latent, or recent serious infections.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Cohort 1: Dose Level A

    Single IV dose at Day 1 and Day 15

    Drug: Budoprutug

  • Experimental
    Cohort 2: Dose Level B

    Single IV dose at Day 1 and Day 15

    Drug: Budoprutug

  • Experimental
    Cohort 3: Dose Level C

    Single IV dose at Day 1 and Day 15

    Drug: Budoprutug

  • Experimental
    Dose Expansion Cohort

    Single IV dose at Day 1 and Day 15

    Drug: Budoprutug

Interventions

  • Single IV dose of study product on Day 1 and Day 15

    Also known as: TNT119

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events (TEAEs)

    Number of participants experiencing TEAEs, graded per NCI CTCAE v6.0.

    Time frame: Up to week 28

  2. Incidence of Clinical Laboratory Abnormalities

    Number of participants with clinically significant laboratory abnomalities.

    Time frame: Up to week 28

  3. Incidence of dose-limiting toxicities (DLTs)

    Number of incidences of dose-limiting toxicities (DLTs)

    Time frame: up to 28 weeks

  4. Change from Baseline in Systolic Blood Pressure

    Mean change from baseline in diastolic blood pressure (mmHg).

    Time frame: Up to week 28

  5. Change from Baseline in Diastolic Blood Pressure

    Mean change from baseline in systolic blood pressure (mmHg).

    Time frame: up to 28 weeks

  6. Change from Baseline in Heart Rate

    Mean change from baseline in heart rate (bpm).

    Time frame: up to 28 weeks

  7. Change from Baseline in Respiratory Rate

    Mean change from baseline in respiratory rate

    Time frame: up to 28 weeks

  8. Change from Baseline in Body Temperature

    Mean change from baseline in body temperature (°C)

    Time frame: up to 28 weeks

  9. Change from Baseline in PR Interval

    Mean change from baseline in PR interval (ms)

    Time frame: up to 28 weeks

  10. Change from Baseline in QRS Duration

    Mean change from baseline in QRS duration (ms)

    Time frame: up to 28 weeks

  11. Change from Baseline in QT Interval

    Mean change from baseline in QT interval (ms)

    Time frame: up to 28 weeks

  12. Change from Baseline in QTc Interval

    Mean change from baseline in corrected QT interval (QTc)

    Time frame: up to 28 weeks

Secondary outcomes

  1. Area Under the Curve (AUC)

    Measurement of the area under the drug concentration-time curve

    Time frame: Up to week 28

  2. Terminal Half-Life (T1/2)

    Measurement of the terminal half-life in days

    Time frame: Up to week 28

  3. Incidence of Anti-Drug Antibodies (ADAs)

    Number of participants with detectable ADAs.

    Time frame: Up to week 28

  4. ADA Titer Over Time

    Measurement of ADA titer over time

    Time frame: Up to week 28

  5. Change from Baseline in CD20+ B-cell Count

    Change in absolute peripheral B-cell count

    Time frame: Up to week 28

  6. Change from Baseline in SLEDAI-2K Score

    Measurement of change in SLEDAI-2K score from baseline

    Time frame: up to 28 weeks

  7. Change from Baseline in Urine Protein Creatinine Ratio (UPCR)

    Measurement of change in UPCR from baseline

    Time frame: up to 28 weeks

07

Study locations

3 of 10 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Sep 2027, 15 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2026
First posted
May 4, 2026
StartActual
Jun 30, 2026
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
8 sites added
Show 8 added (8 China)
  • Baoji Central Hospital · Baoji, China
  • The First Affiliated Hospital of Bengbu Medical College · Bengbu, China
  • Xiangya Second Hospital of Central South University · Changsha, China
  • The First Affiliated Hospital of the University of Science · Hefei, China
  • The First Affiliated Hospital of Nanchang · Nanchang, China
  • The Second Affiliated Hospital of Soochow University · Suzhou, China
  • Shanxi Bethune Hospital · Taiyuan, China
  • Zaozhuang Municipal Hospital · Zaozhuang, China
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    8 sites added
    Show 8 added (8 China)
    • Baoji Central Hospital · Baoji, China
    • The First Affiliated Hospital of Bengbu Medical College · Bengbu, China
    • Xiangya Second Hospital of Central South University · Changsha, China
    • The First Affiliated Hospital of the University of Science · Hefei, China
    • The First Affiliated Hospital of Nanchang · Nanchang, China
    • The Second Affiliated Hospital of Soochow University · Suzhou, China
    • Shanxi Bethune Hospital · Taiyuan, China
    • Zaozhuang Municipal Hospital · Zaozhuang, China
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07564596
Lead sponsor
Climb Bio, Inc.
Responsible party
Sponsor
First posted
May 4, 2026
Start date
Jun 30, 2026
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Oct 20, 2026

Study contacts

Climb Bio Study Director
Contact
clinicaltrials@climbbio.com
+1 8668572596
Study Director
study director · Climb Bio, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budoprutug

Start the discussion